International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Survivorship

  1. Issam Raad
  2. Ray Hachem
  3. Nigo Masayuki
  4. Tarcila Datoguia
  5. Hiba Dagher
  6. Ying Jiang
  7. Vivek Subbiah
  8. Bilal Siddiqui
  9. Arnaud Bayle
  10. Robert Somer
  11. Ana Fernández Cruz
  12. Edward Gorak
  13. Arvinder Bhinder
  14. Nobuyoshi Mori
  15. Nelson Hamerschlak
  16. Samuel Shelanski
  17. Tomislav Dragivich
  18. Yee Elise Vong Kiat
  19. Suha Fakhreddine
  20. Pierre Abi Hanna
  21. Roy F. Chemaly
  22. Victor Mulanovich
  23. Javier Adachi
  24. Jovan Borjan
  25. Fareed Khawaja
  26. Bruno Granwehr
  27. Teny John
  28. Eduardo Yepez Guevara
  29. Harrys Torres
  30. Natraj Reddy Ammakkanavar
  31. Marcel Yibirin
  32. Cielito C Reyes-Gibby
  33. Mala Pande
  34. Noman Ali
  35. Raniv Dawey Rojo
  36. Shahnoor M Ali
  37. Rita E Deeba
  38. Patrick Chaftari
  39. Takahiro Matsuo
  40. Kazuhiro Ishikawa
  41. Ryo Hasegawa
  42. Ramón Aguado-Noya
  43. Álvaro García-García
  44. Cristina Traseira Puchol
  45. Dong-Gun Lee
  46. Monica Slavin
  47. Benjamin Teh
  48. Cesar A Arias
  49. Data-Driven Determinants for COVID-19 Oncology Discovery Effort (D3CODE) Team
  50. Dimitrios P. Kontoyiannis
  51. Alexandre E. Malek
  52. Anne-Marie Chaftari
3 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Background

In this international multicenter study we aimed to determine the independent risk factors associated with increased 30-day mortality and the impact of novel treatment modalities in a large group of cancer and non-cancer patients with COVID-19 from multiple countries.

Methods

We retrospectively collected de-identified data on a cohort of cancer and non-cancer patients diagnosed with COVID-19 between January and November 2020, from 16 international centers.

Results

We analyzed 3966 COVID-19 confirmed patients, 1115 cancer and 2851 non-cancer patients. Cancer patients were more likely to be pancytopenic, and have a smoking history, pulmonary disorders, hypertension, diabetes mellitus, and corticosteroid use in the preceding two weeks (p≤0.01). In addition, they were more likely to present with higher inflammatory biomarkers (D-dimer, ferritin and procalcitonin), but were less likely to present with clinical symptoms (p≤0.01). By multivariable logistic regression analysis, cancer was an independent risk factor for 30-day mortality (OR 1.46; 95% CI 1.03 to 2.07; p=0.035). Older age (≥65 years) was the strongest predictor of 30-day mortality in all patients (OR 4.55; 95% CI 3.34 to6.20; p< 0.0001). Remdesivir was the only therapeutic agent independently associated with decreased 30-day mortality (OR 0.58; CI 0.39-0.88; p=0.009). Among patients on low-flow oxygen at admission, patients who received remdesivir had a lower 30-day mortality rate than those who did not (5.9% vs 17.6%; p=0.03).

Conclusions

Cancer is an independent risk factor for increased 30-day all-cause mortality from COVID-19. Remdesivir, particularly in patients receiving low-flow oxygen, can reduce 30-day all-cause mortality.

Condensed Abstract

In this large multicenter worldwide study of 4015 patients with COVID-19 that included 1115 patients with cancer, we found that cancer is an independent risk factor for increased 30-day all-cause mortality. Remdesivir is a promising treatment modality to reduce 30-day all-cause mortality.

Related articles

Related articles are currently not available for this article.